Articolul precedent |
Articolul urmator |
416 0 |
SM ISO690:2012 TĂRĂBURCĂ, Mihaela, BACHINSKY, N.G.. Bioenergetic inhibitors – a new group of antituberculous drugs. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 30. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | |||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | |||||
|
|||||
Pag. 30-30 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. One way of developing new anti-tuberculosis drugs are inhibitors of energy metabolism, which act on the electron transport chain and oxidative phosphorylation, affecting both growing and dormant bacilli. Objective of the study. The analysis and elucidation of drugs and their targets of action on the energy metabolism of the mycobacteria. Material and Methods. There were selected and analyzed the articles from the PubMed database according to the keywords “latent tuberculosis”, “anti-tuberculosis drugs”, “bioenergetic inhibitors”, “metabolically dormant bacilli”. Results. The analysis of the literature revealed that in contrast to the conventional chemotherapeutics, bioenergetic inhibitors act on the following targets: ATP-synthase (bedaquiline); Cytochrome oxidase (Q203, lansoprazole, aurachin D, microcin J25); NADH dehydrogenase (phenothiazines - chlorpromazine and thioridazine, riminophenazines – clofazimine); Succinate dehydrogenase (3-nitropropionate, siccanin); and menaquinone biosynthesis (SQ109, lysocin E). These drugs can be effective against both multiplying and dormant mycobacteria. Pyrazinamide, pretomanide, delamanide, and nitazoxanide act both on the energy processes and the structural targets of the mycobacteria. Conclusion. Antituberculosis drugs that influence the energy and metabolic processes of the mycobacteria are an important perspective for increasing the effectiveness and development of new regimens for the treatment of tuberculosis, including resistant and latent forms. |
|||||
Cuvinte-cheie antituberculousdrugs, bioenergeticinhibitors, dormantbacilli, preparate antituberculoase, inhibitorii bioenergetici, Mtb dormante |
|||||
|